Featured News

Want to get involved in celiac disease research? It’s time to take action. The TEV-CeD Study is a phase 1b clinical trial testing the investigational medication TEV-53408 for the treatment of celiac disease.  

Congratulations to Celiac Disease Foundation research partner Takeda Pharmaceuticals and its Medical Director Dan Leffler on recent media attention for three potential celiac disease therapies.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

The Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.

The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015.

The Celiac Disease Foundation is in discussion with a team at the University of Colorado, Denver to develop the first-ever, FDA-approved pediatric PRO (patient-reported outcome tool).

A recent study found that avoidant/restrictive food intake disorder (ARFID) is common among people with celiac disease.

Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.

There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.